The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma.

ABSTRACT: Claudin 18.2 (CLDN18.2) is a therapeutically relevant biomarker in esophageal (EAC) -and gastric adenocarcinoma (GAC). Little is known about its heterogeneity within the primary tumor and corresponding metastases and how many biopsies are needed to determine the true CLDN18.2 status of a tumor. CLDN18.2 was assessed in 1,283 patients (822 EAC, 461 GAC), using the antibody clone 43-14 A. Eight virtual endoscopic biopsies were taken from digitized whole tumor blocks. 204 of 822 EAC (24.8%) and 132 of 461 GAC (28,6%) were positive for CLDN18.2. In GAC, CLDN18.2 expression showed a trend towards less invasive growth (p = 0.02) and less common lymph node metastasis (p = 0.07) and was more often observed within the EBV-associated subtype (p = 0.01). When comparing the expression in one biopsy wi

SUBMITTER: Pak S 

PROVIDER: S-EPMC12332122 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature